US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
WO2004009618A2
(en)
*
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
KR20020000223A
(ko)
*
|
1999-05-14 |
2002-01-05 |
존 비. 랜디스 |
표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
|
EP1311291A4
(en)
*
|
2000-08-09 |
2007-07-25 |
Imclone Systems Inc |
TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
WO2002092771A2
(en)
|
2001-05-11 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US7595378B2
(en)
*
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP4303105B2
(ja)
*
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
JP2006506317A
(ja)
|
2002-01-11 |
2006-02-23 |
バイオマリン ファーマシューティカル インコーポレイテッド |
治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
JP2006512895A
(ja)
*
|
2002-06-28 |
2006-04-20 |
ドマンティス リミテッド |
リガンド
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
EP1578801A2
(en)
*
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
CA2450289A1
(en)
*
|
2003-03-20 |
2005-05-19 |
Imclone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
GB0324368D0
(en)
*
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
WO2005068622A2
(en)
*
|
2004-01-20 |
2005-07-28 |
Merus B.V. |
Mixtures of binding proteins
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
AU2005224267B2
(en)
*
|
2004-03-19 |
2011-07-21 |
Imclone Llc |
Human anti-epidermal growth factor receptor antibody
|
JP2008512352A
(ja)
*
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
KR101457753B1
(ko)
|
2004-07-22 |
2014-11-03 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
결합 분자
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
CN101115773B
(zh)
*
|
2005-02-07 |
2015-06-10 |
罗氏格黎卡特股份公司 |
结合egfr的抗原结合分子,编码它的载体,及其应用
|
CN100362018C
(zh)
*
|
2005-03-02 |
2008-01-16 |
上海张江生物技术有限公司 |
重组抗egfr单克隆抗体
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
US20060257317A1
(en)
*
|
2005-05-04 |
2006-11-16 |
Duke University |
Combination therapy in the treatment of cancer
|
JP2008539753A
(ja)
*
|
2005-05-09 |
2008-11-20 |
グリクアート バイオテクノロジー アクチェンゲゼルシャフト |
修飾fc領域およびfc受容体との結合変更を有する抗原結合分子
|
AU2006262232A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
CD19 antibodies and their uses
|
US7449442B2
(en)
*
|
2005-07-12 |
2008-11-11 |
Children's Medical Center Corporation |
EGFR inhibitors promote axon regeneration
|
ES2530265T3
(es)
|
2005-07-21 |
2015-02-27 |
Genmab A/S |
Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
|
ES2539250T3
(es)
|
2005-07-25 |
2015-06-29 |
Emergent Product Development Seattle, Llc |
Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2621363C
(en)
*
|
2005-09-13 |
2015-07-07 |
National Research Council Of Canada |
Methods and compositions for modulating tumor cell activity
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
US8497072B2
(en)
|
2005-11-30 |
2013-07-30 |
Abbott Laboratories |
Amyloid-beta globulomer antibodies
|
PL1954718T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
|
KR20080077238A
(ko)
*
|
2005-12-01 |
2008-08-21 |
도만티스 리미티드 |
인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
|
SG177194A1
(en)
|
2005-12-08 |
2012-01-30 |
Medarex Inc |
Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
|
CN101058609B
(zh)
*
|
2006-05-26 |
2011-04-13 |
神州细胞工程有限公司 |
人源抗体及其表达
|
CA2654317A1
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
US20130004480A1
(en)
|
2006-07-04 |
2013-01-03 |
Paul Parren |
CD20 Binding Molecules for the Treatment of Copd
|
AR062223A1
(es)
*
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
PE20081179A1
(es)
*
|
2006-10-06 |
2008-09-29 |
Amgen Inc |
Formulaciones estables de anticuerpos egfr
|
AU2007309616B2
(en)
*
|
2006-10-20 |
2011-10-06 |
Amgen Inc. |
Stable polypeptide formulations
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
KR101676622B1
(ko)
|
2007-03-01 |
2016-11-17 |
심포젠 에이/에스 |
재조합 항-표피 성장 인자 수용체 항체 조성물
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
MX2009010282A
(es)
*
|
2007-03-29 |
2009-10-12 |
Genmab As |
Anticuerpos biespecificos y metodos para su produccion.
|
BRPI0809594A2
(pt)
*
|
2007-04-03 |
2019-08-27 |
Micromet Ag |
polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
|
WO2008119566A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
EP2666787B1
(en)
|
2007-05-31 |
2022-02-09 |
Genmab A/S |
STABLE IgG4 ANTIBODIES
|
WO2008145140A2
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
NZ580530A
(en)
*
|
2007-06-06 |
2012-04-27 |
Domantis Ltd |
Anti vegf polypeptides, antibody variable domains and antagonists
|
US20100322939A1
(en)
*
|
2007-06-21 |
2010-12-23 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
WO2009030239A1
(en)
|
2007-09-06 |
2009-03-12 |
Genmab A/S |
Novel methods and antibodies for treating cancer
|
CA2703997C
(en)
|
2007-12-26 |
2017-04-04 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
JP6014706B2
(ja)
*
|
2008-02-14 |
2016-10-25 |
株式会社イーベック |
hGM−CSFに結合するモノクローナル抗体および前記抗体を含む医薬組成物
|
WO2009126306A2
(en)
*
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
CN105198997B
(zh)
|
2008-04-11 |
2018-08-31 |
阿普拜佛研发有限责任公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
BRPI0913406A2
(pt)
|
2008-06-03 |
2018-01-09 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
CN101602808B
(zh)
*
|
2008-06-12 |
2012-06-20 |
上海市肿瘤研究所 |
特异性结合蛋白及其使用
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
AU2013202396B2
(en)
*
|
2008-07-16 |
2014-07-10 |
Institute For Research In Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
WO2010022736A2
(en)
|
2008-08-29 |
2010-03-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
BRPI0917315B8
(pt)
*
|
2008-11-07 |
2021-05-25 |
Galaxy Biotech Llc |
anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
|
CN102300879A
(zh)
*
|
2008-12-04 |
2011-12-28 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
NZ611324A
(en)
|
2009-03-05 |
2015-02-27 |
Abbvie Inc |
Il-17 binding proteins
|
GB0905023D0
(en)
*
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
RU2012112550A
(ru)
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
KR101108642B1
(ko)
|
2009-09-29 |
2012-02-09 |
주식회사 녹십자 |
표피 성장 인자 수용체에 특이적으로 결합하는 항체
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN101875695B
(zh)
*
|
2009-11-11 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其编码基因与应用
|
CN101875696B
(zh)
*
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
CA2776513C
(en)
|
2009-11-24 |
2017-08-01 |
Alethia Biotherapeutics Inc. |
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
CN103097417B
(zh)
|
2010-04-20 |
2019-04-09 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
CN105001330B
(zh)
†
|
2010-04-23 |
2020-05-01 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
PE20130205A1
(es)
|
2010-05-14 |
2013-03-24 |
Abbvie Inc |
Proteinas de union a il-1
|
US20120093733A1
(en)
*
|
2010-05-24 |
2012-04-19 |
Marek Malecki |
Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
JP6093696B2
(ja)
|
2010-06-09 |
2017-03-08 |
ゲンマブ エー/エス |
ヒトcd38に対する抗体
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
KR101273918B1
(ko)
*
|
2010-09-17 |
2013-06-13 |
강원대학교산학협력단 |
인간 항-상피세포성 성장인자수용체 Fab 항체 및 이를 포함하는 종양 치료용 약학 조성물
|
WO2012047225A2
(en)
*
|
2010-10-08 |
2012-04-12 |
The General Hospital Corporation |
Methods of treating liver fibrosis and pre-cirrhosis with epidermal growth factor receptor inhibitors
|
BR112013010569A2
(pt)
*
|
2010-10-29 |
2017-07-04 |
Immunogen Inc |
moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma
|
MX2013004761A
(es)
|
2010-10-29 |
2013-08-27 |
Immunogen Inc |
Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
|
US8853365B2
(en)
|
2010-12-21 |
2014-10-07 |
Abbvie Inc. |
Dual variable domain immunnoglobulins and uses thereof
|
JP5908972B2
(ja)
*
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
CN102262155B
(zh)
*
|
2011-04-12 |
2013-10-09 |
百泰生物药业有限公司 |
重组人表皮生长因子生物学活性测定方法及其应用
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
AU2012244675B2
(en)
|
2011-04-21 |
2017-06-29 |
Seattle Genetics, Inc. |
Novel binder-drug conjugates (ADCs) and their use
|
HUE029855T2
(hu)
|
2011-07-05 |
2017-04-28 |
Bioasis Technologies Inc |
p97-antitest konjugátumok
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
EA201791393A3
(ru)
|
2011-09-30 |
2018-03-30 |
Ридженерон Фармасьютикалз, Инк. |
Антитела к erbb3 и их применение
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
KR102049803B1
(ko)
|
2011-10-27 |
2019-11-29 |
젠맵 에이/에스 |
이종이량체 단백질의 생산
|
JP6149042B2
(ja)
*
|
2011-11-09 |
2017-06-14 |
ザ ユーエービー リサーチ ファンデーション |
Her3抗体およびその使用
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
CA2856297C
(en)
|
2011-11-23 |
2023-10-17 |
Medimmune, Llc |
Binding molecules specific for her3 and uses thereof
|
SI2782598T1
(sl)
*
|
2011-11-23 |
2020-12-31 |
In3Bio Ltd. |
Rekombinantni proteini in njihove terapevtske uporabe
|
CN103172741B
(zh)
*
|
2011-12-20 |
2018-04-27 |
智翔(上海)医药科技有限公司 |
全人源抗egfr抗体
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
ES2694679T3
(es)
*
|
2012-03-27 |
2018-12-26 |
Green Cross Corporation |
Epitopos de antígeno de superficie receptor de factor de crecimiento epidérmico y uso de los mismos
|
KR20230091201A
(ko)
|
2012-04-20 |
2023-06-22 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
CA2872018A1
(en)
*
|
2012-05-17 |
2013-11-21 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind egfr
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
PT2869845T
(pt)
*
|
2012-07-06 |
2019-12-09 |
Genmab Bv |
Proteína dimérica com mutações triplas
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
CA2880162C
(en)
|
2012-07-31 |
2023-04-04 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
WO2014036492A1
(en)
|
2012-08-31 |
2014-03-06 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
US20150266970A1
(en)
*
|
2012-10-24 |
2015-09-24 |
Yeda Research And Development Co. Ltd. |
Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
|
JP6109952B2
(ja)
|
2012-11-01 |
2017-04-05 |
アッヴィ・インコーポレイテッド |
抗vegf/dll4二重可変ドメイン免疫グロブリンおよびこれらの使用
|
CN102993305B
(zh)
*
|
2012-11-16 |
2015-05-13 |
上海赛伦生物技术有限公司 |
人源抗人表皮生长因子受体抗体及其编码基因与应用
|
US9695228B2
(en)
*
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
JP6423357B2
(ja)
*
|
2012-11-21 |
2018-11-14 |
ヤンセン バイオテツク,インコーポレーテツド |
二重特異性EGFR/c−Met抗体
|
EP2943506B1
(en)
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
RU2528414C1
(ru)
|
2013-01-25 |
2014-09-20 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
|
US9364567B2
(en)
|
2013-03-13 |
2016-06-14 |
Bioasis Technologies, Inc. |
Fragments of p97 and uses thereof
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
RU2652880C2
(ru)
*
|
2013-04-07 |
2018-05-03 |
Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. |
Антитело против рецептора эпидермального фактора роста
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
DK3086814T3
(da)
|
2013-12-23 |
2020-09-14 |
Bayer Pharma AG |
Binder-konjugater (adcs) med ksp-inhibitorer
|
CA2935195A1
(en)
|
2014-02-03 |
2015-08-06 |
Bioasis Technologies, Inc. |
P97 fusion proteins
|
BR112016018721A2
(pt)
|
2014-02-19 |
2017-10-10 |
Bioasis Technologies Inc |
proteínas de fusão p97-ids
|
US9822186B2
(en)
|
2014-03-28 |
2017-11-21 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
WO2015157634A1
(en)
|
2014-04-11 |
2015-10-15 |
Kolltan Pharmaceuticals, Inc. |
Anti-erbb antibodies and methods of use thereof
|
US10058619B2
(en)
|
2014-05-01 |
2018-08-28 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
BR112016024462B1
(pt)
|
2014-05-06 |
2022-12-27 |
Genentech, Inc |
Métodos para a preparação de um anticorpo
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
CA2959841A1
(en)
|
2014-10-23 |
2016-04-28 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
MA55043A
(fr)
|
2014-11-26 |
2021-12-29 |
Xencor Inc |
Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
MA41019A
(fr)
|
2014-11-26 |
2021-05-05 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
DK3233907T3
(da)
|
2014-12-19 |
2021-06-07 |
Genmab As |
Bispecifikke heterodimeriske proteiner hos gnavere
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
WO2016171365A1
(ko)
*
|
2015-04-23 |
2016-10-27 |
신일제약주식회사 |
Egfr에 특이적으로 결합하는 fab단편
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN108025084A
(zh)
|
2015-06-22 |
2018-05-11 |
拜耳医药股份有限公司 |
具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc)
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
EA038329B1
(ru)
|
2015-08-28 |
2021-08-10 |
Амьюникс Фармасьютикалз, Инк. |
Химерный полипептидный комплекс и способы его получения и применения
|
BR112018005573A2
(pt)
|
2015-09-21 |
2019-01-22 |
Aptevo Research And Development Llc |
?polipeptídeos de ligação a cd3?
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
CN108289952B
(zh)
*
|
2015-11-19 |
2021-02-05 |
雷维托普有限公司 |
用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
PE20181852A1
(es)
|
2016-03-24 |
2018-12-03 |
Bayer Pharma AG |
Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
CN109641047A
(zh)
|
2016-05-20 |
2019-04-16 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
KR102523402B1
(ko)
|
2016-06-14 |
2023-04-19 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
EP3472197A1
(en)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
CN109310781A
(zh)
|
2016-06-15 |
2019-02-05 |
拜耳制药股份公司 |
具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
AU2017380871A1
(en)
|
2016-12-21 |
2019-07-11 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (ADCs) having enzymatically cleavable groups
|
WO2018114798A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
CN110072556B
(zh)
|
2016-12-21 |
2023-05-02 |
拜耳制药股份公司 |
具有ksp抑制剂的特异性抗体药物缀合物(adc)
|
KR102616666B1
(ko)
|
2016-12-23 |
2023-12-27 |
노파르티스 아게 |
인자 xi 항체 및 사용 방법
|
AU2018218345A1
(en)
|
2017-02-10 |
2019-08-29 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
メソテリン結合タンパク質
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
JP2021506291A
(ja)
|
2017-12-19 |
2021-02-22 |
ゼンコア インコーポレイテッド |
改変されたil−2 fc融合タンパク質
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
CN112513074A
(zh)
|
2018-06-22 |
2021-03-16 |
健玛保 |
生产两种或更多种不同抗体的受控混合物的方法
|
CN113286817A
(zh)
|
2018-09-25 |
2021-08-20 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
CN113195523A
(zh)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12异源二聚体Fc融合蛋白
|
WO2020136145A2
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor neutralizing antibodies
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114585645A
(zh)
*
|
2019-08-09 |
2022-06-03 |
A2生物治疗公司 |
对杂合性丧失作出响应的细胞表面受体
|
EP4069245A1
(en)
|
2019-12-02 |
2022-10-12 |
Celgene Corporation |
Therapy for the treatment of cancer
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
KR20230052291A
(ko)
|
2020-08-20 |
2023-04-19 |
에이투 바이오쎄라퓨틱스, 인크. |
Ceacam 양성 암을 치료하기 위한 조성물 및 방법
|
IL300500A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of mesothelin positive cancer
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
KR102415292B1
(ko)
|
2022-04-04 |
2022-07-01 |
(주)청수 |
고농도 복합 악취 처리시스템
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|